Radioactive 'Smart Bomb' targets cancer in new human trial
NCT ID NCT06305962
First seen Feb 20, 2026 · Last updated Jun 19, 2026 · Updated 15 times
Summary
This early-phase trial is testing a new drug called 177Lu-RAD204, which is a radioactive antibody designed to seek out and attack cancer cells that have a protein called PD-L1 on their surface. The study will involve about 30 adults with advanced solid tumors (like lung, breast, or skin cancer) that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how it spreads in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Research SA (CRSA)
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact Email: •••••@•••••
-
GenesisCare Murdoch
RECRUITINGMurdoch, Western Australia, 6150, Australia
Contact Email: •••••@•••••
-
Gold Coast University Hospital
RECRUITINGSouthport, Queensland, 4215, Australia
Contact Email: •••••@•••••
-
Nepean Hospital
RECRUITINGKingswood, New South Wales, 2747, Australia
Contact Email: •••••@•••••
-
Wollongong Hospital
RECRUITINGWollongong, New South Wales, 2500, Australia
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-RAD204 (a radioactive antibody that targets PD-L1 on cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for several hard-to-treat cancers that have spread.
What could go wrong
This is a very early (Phase 0/1) and small trial with only 30 people. The main goal is safety, not effectiveness, and the radioactive drug may cause side effects like damage to kidneys or bone marrow.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.